Senti Biosciences board member Brenda Cooperstone resigns effective immediately
The company disclosed in a September 24, 2026 filing that Cooperstone stepped down from the board and her committee post on September 23, citing no dispute with the company.
Senti Biosciences Holdings, Inc. disclosed in an 8-K filed September 24, 2026 that Brenda Cooperstone, Ph.D., notified the company's board of directors on September 23, 2026 of her decision to resign from the board, effective immediately.1
Along with leaving the board, Cooperstone also gave up her position as a member and chair of the board's Compensation Committee, with that resignation taking effect immediately as well.1
The filing states that her departure did not stem from any disagreement with the company over its operations, policies, or practices.1
The company also included a brief note acknowledging her contributions and service to the company and the board.1
The 8-K was signed on September 24, 2026 by Timothy Lu, M.D., Ph.D., the company's Chief Executive Officer. Senti Biosciences Holdings trades under the ticker SNTI on The Nasdaq Capital Market and is based in South San Francisco, California. The filing did not name a replacement for Cooperstone's board or committee roles.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.